O'HEERON PETE 4

What Happened Pete O'Heeron, CEO of FibroBiologics, was granted an option to purchase 92,410 shares of common stock (reported as an "A" acquisition) on May 4, 2026. The filing records the acquisition at $0.00 because this is an option grant (a derivative award), not a cash purchase or sale. No immediate exercise or sale of shares was reported.

Key Details

• Transaction date: 2026-05-04; transaction type: Option grant (derivative) reported as "A"
• Shares/units: 92,410 option shares; price recorded: $0.00 (reflects grant, not exercise)
• Vesting: 1/4 of the option vests on the one-year anniversary of the grant; remaining shares vest in 36 equal monthly installments thereafter (per footnote)
• Shares owned after transaction: Not specified in this Form 4
• Filing timeliness: Reported on the same date (timely); no late filing indicated

Context This is a standard equity-compensation grant to an executive. Option grants do not immediately increase outstanding common shares unless and until options are exercised; the economic value depends on the option's exercise price and the company's future stock price. The reported vesting schedule imposes service-based vesting over roughly four years.